Las Vegas, NV -- (SBWIRE) -- 12/24/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is on: U.S. Bancorp (NYSE:USB), Banro Corporation (USA) (NYSEMKT:BAA), Galena Biopharma Inc (NASDAQ:GALE), Merck & Co., Inc. (NYSE:MRK)
U.S. Bancorp (NYSE:USB) managed to keep its gain at 1.10% on below -normal volume of 8.44M shares. The stock settled at $40.49 after floating in a range of $40.17 to $40.81. Its latest price has reached market capitalization of $73.95 billion. Its 52-week range has been $31.50 to $40.81. U.S. Bancorp (U.S. Bancorp) is a multi-state financial services holding company. It provides a range of financial services, including lending and depository services, cash management, foreign exchange and trust and investment management services. It also engages in credit card services, merchant and automated teller machine (ATM) processing, mortgage banking, insurance, brokerage and leasing.
For How Long USB will fight for Profitability? Read This Trend Analysis report
Banro Corporation (USA) (NYSEMKT:BAA) traded down on a volume of 1.18 million, higher than its standard daily volume. Shares have dropped-2.55% to $0.420. Over the last twelve months, the stock has lost-84.44% and faced a worst price of $0.41. Banro Corporation (Banro) is a Canada-based gold exploration company. The Company holds, through four wholly owned subsidiaries, a 100% interest in four gold properties, which are known as Twangiza, Namoya, Lugushwa and Kamituga. These properties are covered by a total of 13 exploitation permits and are found along the 210 kilometer-long Twangiza-Namoya gold belt in the South Kivu and Maniema Provinces of eastern Democratic Republic of the Congo (DRC).
Has BAA Found The Bottom And Ready To Gain Momentum? Find Out Here
Galena Biopharma Inc (NASDAQ:GALE) settled 0.25% higher at $4.04 on below -normal volume of 2.55M shares during the last trading day. The stock has its 12-month high at $4.78 and 52-week low price was $1.48. It traded in a range of $4.01 to $4.15 during the last trading day. Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche).
Why Should Investors Buy GALE After the Recent Fall? Just Go Here and Find Out
In the last trading session, Merck & Co., Inc. (NYSE:MRK) was up on low volume, trading at a volume of 8.27M shares versus its average daily volume of 12.06 million shares. At $49.36, the stock has attained market capitalization of $144.46 billion. Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Will MRK Continue To Move Higher? Find Out Here
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)